CIK 0001736243 · <br>Emerging growth company
Acurx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ACXP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 917-533-1469
- Business address
- 259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305
- Former names
- Acurx Pharmaceuticals, LLC
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 19,737 shares at $3.80 ($75,001)
- 4 Open-market buy Director bought 19,737 shares at $3.80 ($75,001)
- 4 Open-market buy President and CEO bought 19,737 shares at $3.80 ($75,001)
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Results of operations · Unregistered share sale · Code of ethics change
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 8-K Event Shareholder vote results
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Results of operations
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 4 Open-market buy Director bought 5,161 shares at $4.84 ($24,979)
- 4 Open-market buy Director bought 5,034 shares at $4.90 ($24,672)
Page 10 of 13 · 246 filings